Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database

Clinical Microbiology and Infection

Volumn 19, Issue 10, 2013, Pages 936-942

  Rusconi, S ^a   Vitiello, P ^a   Adorni, F ^b   Bruzzone, B ^c   De Luca, A ^d   Micheli, V ^a   Meraviglia, P ^a   Maserati, R ^e   Di Pietro, M ^f   Colao, G ^g   Penco, G ^h   Di Biagio, A ^c   Punzi, G ⁱ   Monno, L ^j   Zazzi, M ^k  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f Ospedale S M Annunziata   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h GALLIERA HOSPITAL   (Italy)

ⁱ POLICLINICO   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k UNIVERSITY OF SIENA   (Italy)

more..

Author keywords

Drug resistance; Genotype; human immunodeficiency virus type 1 1; Raltegravir; Virological response

Indexed keywords

RALTEGRAVIR; VIRUS RNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

DRUG RESISTANCE; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-1; RALTEGRAVIR; VIROLOGICAL RESPONSE;

ADULT; ANTI-HIV AGENTS; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRROLIDINONES; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT FAILURE;

EID: 84884730779     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12100     Document Type: Article

References (29)

1. Semenova EA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: update and perspectives. Adv Pharmacol 2008; 56: 199-228.
2. Garrido C, Soriano V, de Mendoza C. New therapeutic strategies for raltegravir. J Antimicrob Chemother 2010; 65: 218-223.
3. Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50: 605-612.
4. Lennox JL, DeJesus E, Berger DS et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
5. Ceccherini-Silberstein F, Malet I, Fabeni L et al. Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors. J Antimicrob Chemother 2010; 65: 2305-2318.
6. Varghese V, Liu TF, Rhee SY et al. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir. AIDS Res Hum Retroviruses 2010; 26: 1323-1326.
7. Margeridon-Thermet S, Shafer RW. Comparison of the mechanisms of drug resistance among HIV, Hepatitis B, and Hepatitis C. Viruses 2010; 2: 2696-2739.
8. Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764-774.
9. Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83: 11440-11446.
10. da Silva D, Van Wesenbeeck L, Breilh D et al. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J Antimicrob Chemother 2010; 65: 1262-1269.
11. Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 2010; 54: 934-936.
12. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; 67: 2494-2500.
13. Blanco JL, Martinez-Picado J. HIV integrase inhibitors in ART-experienced patients. Curr Opin HIV AIDS 2012; 7: 415-421.
14. Zazzi M, Prosperi M, Vicenti I et al. Rules-based HIV-1 genotypic resistance interpretation systems predict 8-week and 24-week virological antiretroviral treatment outcome and benefit from drug potency weighting. J Antimicrob Chemother 2009; 64: 616-624.
15. Johnson VA, Calvez V, Günthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156-164.
16. Eron J, Rockstroh J, Reynes J et al. QDMRK, a phase III study of the safety and efficacy of once daily vs twice daily RAL in combination therapy for treatment-naive HIV-infected patients. Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, Massachusetts. Abstract 150LB.
17. Lazzarin A, Dejesus E, Rockstroh J et al. Durable and consistent efficacy of raltegravir (RAL) with tenofovir (TDF) and emtricitabine (FTC) across demographic and baseline prognostic factors in treatment-naïve patients (pts) from STARTMRK at Wk 156. Program and abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, Illinois. Abstract H2-790.
18. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004; 53: 696-699.
19. Hatano H, Lampiris H, Fransen S et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J AIDS 2010; 54: 398-393.
20. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-365.
21. Rhee SY, Fessel WJ, Liu TF et al. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009; 200: 453-463.
22. Malet I, Fourati S, Morand-Joubert L et al. Risk factors for raltegravir resistance development in clinical practice. J Antimicrob Chemother 2012; 61: 297-301.
23. Zaccarelli M, Lorenzini P, Marconi P et al. Is extended resistance to the historical antiretroviral drugs and drug classes still a risk factor for HIV progression [abstract P138]. In: Program and abstracts of the Tenth International Congress on Drug Therapy in HIV Infection, 7-11 November 2010, Glasgow, UK, 2010:66.
24. Ferns RB, Kirk S, Bennett J, Williams I, Edwards S, Pillay D. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009; 23: 2159-2164.
25. Garrido C, Geretti AM, Zahonero N et al. Integrase variability and susceptibility to integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010; 65: 320-326.
26. Codoñer FM, Pou C, Thielen A et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 2010; 88: 281-286.
27. Charpentier C, Laureillard D, Piketty C et al. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010; 24: 867-873.
28. Liu J, Miller MD, Danovich RM et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 2011; 55: 1114-1119.
29. Ceccherini-Silberstein F, Van Baelen K, Armenia D et al. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 2010; 54: 3938-3948.